Medtronic voluntarily initiated a Class II recall of 590 Octopus 4 Tissue Stabilizer devices in May 2026 after discovering an assembly issue in the tubing configuration, with the US FDA listing the action as an ongoing enforcement event affecting worldwide distribution. Around the same time, the company reported fiscal Q3 2024 earnings per share of US$1.30 on revenue of US$8.09 billion, exceeding expectations. The recall appears limited in scope and does not obviously alter the near-term focus on margin recovery, though it highlights the balance between quality-control challenges and financial execution. Medtronic's narrative projects US$41.5 billion in revenue and US$6.6 billion in earnings by 2029, requiring 4.5% yearly revenue growth and about a US$1.8 billion earnings increase from US$4.8 billion today. Some analysts already assumed only about 2% annual revenue growth to roughly US$38.6 billion and EPS near US$4.89 by 2029, and this latest recall could push their more cautious view on execution and quality control even further.
Medtronic PLCFiscal Q3 2024 earnings beat expectations with EPS of $1.30 on revenue of $8.09B.